RxSight stock faces a lower Jefferies target at USD 5.75

Published on 10/01/2026 at 06:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RxSight stock posted an adjusted Q2 2026 loss of USD 0.29 per share, beating USD 0.33 consensus on August 5, 2026. BofA cut its target to USD 5.50.

RXST, US78419L1008, Illustration mit AI erstellt.

RxSight, Inc. (ISIN US78419L1008) reported Q2 2026 revenue of USD 33.74 million and an adjusted loss of USD 0.29 per share for the quarter ended June 30, 2026. The result was stronger than the USD 0.33 consensus loss, but the company remained unprofitable.

Jefferies lowers its target

The latest analyst signal is cautious. On September 22, 2026, Markets Insider reported that Jefferies reduced its RxSight price target from USD 6.50 to USD 5.75 and maintained a Hold rating.

The revision contrasts with the quarterly beat. MarketBeat reported on September 22, 2026, that Bank of America cut its target from USD 6.50 to USD 5.50 and kept an Underperform rating. The same report cited a consensus target of USD 8.26 and an average Reduce rating across covered analysts.

Revenue beat meets operating pressure

RxSight's Q2 revenue exceeded the USD 32.55 million analyst estimate by USD 1.19 million, while the adjusted loss was USD 0.04 per share better than consensus, according to MarketBeat. That combination gives investors a clearer split between quarterly execution and the longer-term utilization debate.

RxSight describes its business as a commercial-stage medical technology company built around the FDA-approved Light Adjustable Lens system. The platform combines the lens with a Light Delivery Device that enables doctors to customize visual acuity after cataract surgery.

Stock remains near its yearly low

RxSight was last at USD 4.90 on Nasdaq on September 30, 2026 at 4:00 p.m. ET. Its 52-week range was USD 4.48 to USD 13.22, while market capitalization stood at USD 202.8 million on September 30, 2026.